C. Von Arx - Dept Surg & Canc, Imperial Coll London

基本信息

浏览量：1

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 16 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

158TiP Neoadjuvant abemaciclib and giredestrant trial in patients with ER-positive, HER2-negative early breast cancer (GIM31-Neo-AGILE trial)

C. von Arx,A. Calabrese, R. Caputo,V. Di Lauro,M. Pensabene,G. Buono,A. Fabi,F. Cognetti,V. Guarneri,F. Puglisi,P. Vigneri,L. Del Mastro,G. Arpino,M. De Laurentiis

ESMO Open (2024)

引用0浏览0引用

Prevention, diagnosis and clinical management of hereditary breast cancer beyond BRCA1/2 genes

A. Calabrese,C. von Arx, A.A. Tafuti,M. Pensabene,M. De Laurentiis

Cancer Treatment Reviews (2024)

引用0浏览0引用

A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial

C. von Arx,G. Della Vittoria Scarpati,L. Cannella,O. Clemente,A. L. Marretta,A. Bracigliano,F. Picozzi,D. Iervolino,V. Granata,R. Modica,A. Bianco,C. Mocerino,A. Di Mauro,A. Pizzolorusso,A. Di Sarno,A. Ottaiano,S. Tafuto

ESMO Openno. 5 (2024): 103003-103003

引用0浏览0WOS引用

Prevention, diagnosis and clinical management of hereditary breast cancer beyond BRCA1/2 genes

A. Calabrese,C. von Arx, A.A. Tafuti,M. Pensabene,M. De Laurentiis

Cancer Treatment Reviews (2024): 102785-102785

引用0浏览0WOS引用

Cancer genetic counselling for hereditary breast cancer in the era of precision oncology

M. Pensabene,A. Calabrese,C. von Arx,R. Caputo,M. De Laurentiis

CANCER TREATMENT REVIEWS (2024): 102702-102702

引用0浏览0WOS引用

1200P A phase II single-arm interventional trial evaluating the activity and safety of CABOzantinib (CBZ) plus TEMozolomide (TMZ) in lung and gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) progressed after SSA therapy, everolimus, sunitinib or PRRT: CABOTEM Trial

O. Clemente, N. Starita,A. Bracigliano,M. Cives,F. Tatangelo, M.L. Barretta,G. Badalamenti,S. Lastoria,F. Picozzi,A. Di Mauro,C. von Arx,L. Cannella,S. Tafuto

Annals of Oncology (2023): S708-S708

引用0浏览0引用

1202P Final Analysis of TENEC Trial: A Phase II Trial of Temozolomide (TMZ) As Second-Line Treatment for Advanced Neuroendocrine Carcinomas (NEC) in Patients (pts) with a Poor Performance Status (PS)

C. von Arx,L. Cannella,A. L. Marretta,A. Bracigliano,F. Tatangelo,O. Clemente,D. Iervolino,V. Granata,C. Mocerino,R. Modica,A. Pizzolorusso,A. Bianco,F. Picozzi,A. Di Sarno,S. Tafuto

Annals of Oncology (2023): S708-S709

引用0浏览0引用

449P Cyclin-dependent Kinase 4/6 Inhibitors (cdk4/6i) Plus Endocrine Therapy (ET) Treatment in Metastatic Lobular Breast Cancer (mlbc): A Retrospective Cohort Study

C. von Arx,A. Calabrese, C. Martinelli,V. Di Lauro, V. Grimaldi,M. Pensabene, R. Caputo,I. Cerillo,D. Cianniello,G. Buono,A. Verrazzo,C. Pacilio,F. Di Rella,F. Nuzzo,M. De Laurentiis

Annals of Oncology (2023): S370

引用0浏览0引用

105P CDK4/6 inhibitors in hormone receptor-positive, HER2-negative, locally advanced breast cancer (LABC): Biological and clinical activity, and post-surgical approaches

S. Parola,V. Di Lauro,P. De Placido,V. Forestieri,G. Buono,C. von Arx,E. Pietroluongo,M. Pagliuca,D. Cianniello,R. Lauria, R. Caputo,G. Arpino,S. de Placido,M. Giuliano,M. De Laurentiis,C. De Angelis

Annals of Oncology (2022): S172-S173

引用2浏览0引用

A phase II single arm trial evaluating the efficacy and safety of Temozolomide for second-line treatment of neuroendocrine carcinomas progressing after first-line platinum-based therapy

L. Cannella,C. von Arx,A. Bracigliano,A. Pizzolorusso, D. S. Antonella,O. Clemente,R. Modica,M. Di Marzo,F. Tatangelo,S. Tafuto

JOURNAL OF NEUROENDOCRINOLOGY（2022）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn